Skip to main content
. Author manuscript; available in PMC: 2021 Nov 10.
Published in final edited form as: J Control Release. 2020 Aug 21;327:406–419. doi: 10.1016/j.jconrel.2020.08.026

Figure 7.

Figure 7.

(A) miR-155 levels in SUDHL-5 cells after treatment with PLGA NPs containing antimiR-155 PNAs at the equivalent dose of 2.5 nmol relative to normalized average control U6 (n=3, *p<0.05). AntimiR-155 (mirVana miR-155 inhibitor) transfection was used as a positive control. (B) Dose dependent effect on SUDHL-5 cells treated with NPs containing indicated antimiR PNAs. Cell viability measured using trypan blue dye (n=3, data represented as mean ± standard error mean (SEM)). For statistical analysis student t-test was used.